BACKGROUND: There is a persistent racial survival disparity between African American (AA) and white women with breast cancer. There is evidence that symptom incidence, associated distress, and overall cancer-related distress may be unexplored, important contributing factors. The purpose of the current study was to: 1) describe and compare the number of chemotherapy-related symptoms and associated distress among AA women with breast cancer over the course of chemotherapy at 3 time points (at baseline before initiating chemotherapy, midpoint, and at the completion of chemotherapy); and 2) to describe the relationship between the number of chemotherapy-related symptoms and overall cancer distress compared with the ability to receive at least 85% of the prescribed chemotherapy within the prescribed timeframe. METHODS: Descriptive, comparative, and correlational analyses of symptom incidence, symptom distress, cancer-related distress, and prescribed chemotherapy dose received among a cohort of AA women receiving chemotherapy for breast cancer were performed. RESULTS: AA women (121 women) experienced worsening symptoms from baseline to midpoint in chemotherapy and then stabilized for the duration of therapy. The inability to receive 85% of the prescribed chemotherapy within a prescribed time point was found to be significantly correlated with midpoint symptom distress. CONCLUSIONS: The main findings of the current study were that AA women experience a deterioration in symptom distress over the course of chemotherapy from baseline (before chemotherapy) to the midpoint, which was found to be associated with less adherence to chemotherapy overall. Thus, the incidence and management of physical and emotional symptoms, as measured through a multidimensional symptom measurement tool, may be contributing to breast cancer dose disparity and should be explored further. Cancer 2017;123:2061-9. V C 2017 American Cancer Society.
INTRODUCTION
A significant survival disparity still exists between African American (AA) and white women diagnosed with breast cancer. The etiology is multifactorial. The Institute of Medicine's classic model of health disparity focuses on patient preferences, discrimination (including clinicians' bias and stereotyping), and the overall operation of the health system as the foundational elements of health care disparity. 1 A closer examination of symptom toxicity and overall distress during breast cancer treatment may provide clinically actionable targets for the mitigation of racial disparities in breast cancer treatment. The purpose of the current study was to describe chemotherapy-related symptoms and overall cancer-related distress among AA women with breast cancer over the course of chemotherapy. The secondary objective was to describe the correlation of these symptoms and distress with the ability to receive at least 85% of prescribed chemotherapy treatments (which is associated with better outcomes) within a prescribed time frame.
Background
The breast cancer survival disparity between AA women and non-Hispanic white women has been well documented.
2-8 -Advances in breast cancer treatment have led to an overall improvement in breast cancer survival, but AA women are not benefiting at equal rates compared with white women. After a first diagnosis of breast cancer, the 5-year survival rate is reported to be 89% for white women but only 75% for AA women. 9 Historically, the survival disparity in AA women has been attributed to incidence at an earlier age, later stage of disease at presentation, or inherent differences in tumor biology. [10] [11] [12] However, these factors do not explain all racial variations in breast cancer survival.
Treatment, specifically chemotherapy, disparity in cancer is an understudied aspect of potential etiological factors for survival disparity. It is clear that breast cancer chemotherapy maximizes benefits, lowers rates of breast cancer recurrence, and improves survival among appropriately selected patients. The timing of treatment initiation is important, and delays in treatment are associated with worse survival. 13 Historically, AA patients have been shown to have a longer time to breast cancer diagnosis and experience longer times to the initiation of adjuvant chemotherapy compared with white patients. [14] [15] [16] The racial disparity previously documented in breast cancer chemotherapy choice and dose by physicians and initiation may be diminishing. Although chemotherapy decisions are made by physicians, the treatment choices in today's cancer care environment often are standardized by institutional guidelines, treatment algorithms such as the National Comprehensive Cancer Network (NCCN), and mandates to not limit chemotherapy according to weight. [17] [18] [19] [20] This practice helps to remove unintentional provider racial bias and ensure that all patients receive equitable cancer treatment specific to tumor staging and biological characteristics. However, racial differences in the ability to receive the full dose of prescribed chemotherapy on time are evident, 21 leading to disparity in breast cancer treatment over the treatment trajectory.
Explanatory factors for breast cancer treatment disparity are possible racial differences in symptom incidence, cancer-related distress, and communication surrounding symptom reporting. While receiving breast cancer chemotherapy, it has been documented that AA women experience more severe symptoms than white women, particularly pain and neuropathy. 22, 23 These differences have been established at baseline (before chemotherapy) and across the breast cancer treatment trajectory. 24 Each patient's ability to tolerate treatment ultimately may affect her adherence. Patients with worse or poorly controlled treatment-related symptoms may be more likely to discontinue treatment early through their requests or nonadherence to appointments, or through clinical decisions to limit ongoing toxicity. In 2008, Paskett et al explored the quality of life in a racially diverse cohort of women through breast cancer treatment, 25 and suggested that symptoms played a role in worse functional outcomes. This study did not extend the measurement to the ability to receive the full dose of chemotherapy.
The racial impact of the role of symptoms and symptom distress in the ability to receive the full dose of prescribed chemotherapy is a gap in our understanding and is the purpose of the current study.
Adherence to a therapeutic regimen has been broadly defined as the ability to initiate and receive the full course treatment as prescribed within an appropriate time frame. The International Society for Pharmacoeconomics and Outcomes Research proposes a definition of medication compliance/adherence as "the degree or extent of conformity (most appropriately a percentage) to the recommendations about day-to-day treatment by the provider with respect to the timing, dosage, and frequency." 26 Many studies of adherence to therapy measure the initiation of chemotherapy, but do not assess the timing or number of doses received after the initial dose of chemotherapy. The concept of relative dose intensity, the percentage of chemotherapy prescribed over the percentage received within a specific time frame, has been proposed to help quantify the concept of adherence to therapy in breast cancer. A relative dose intensity of 85% of the prescribed chemotherapy within a specific time frame is associated with worse survival outcomes. 27 The objectives of the current study were to: 1) describe chemotherapy-related symptoms, total number of symptoms, associated distress, and overall cancer distress among AA women with breast cancer over the course of chemotherapy at 3 time points (baseline before chemotherapy, midpoint, and at the completion of chemotherapy) for the entire cohort; and 2) to describe the relationship over time between chemotherapy-related symptoms, associated distress, and overall cancer distress and the ability to receive 85% of the prescribed chemotherapy within the prescribed time frame for the entire cohort.
MATERIALS AND METHODS

Design
The current study was a secondary, exploratory aim from the Attitudes, Communication, Treatment, and Support (ACTS) Intervention to Reduce Breast Cancer Treatment Disparity study, which is a randomized controlled trial of a psychoeducational intervention to encourage acceptance and adherence to chemotherapy compared with usual care for AA women with breast cancer. It was conducted from 2011 through 2015. 28 Second, the ACTS study proposed to explore the influence of ACTS on proximal outcomes that may influence chemotherapy adherence including: 1) quality of life; 2) symptom incidence and distress; and 3)
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Subject Eligibility
AA women aged 18 years who were diagnosed with any stage of invasive breast cancer were screened to participate. AA race was determined by patient self-report on their demographic form, which was completed at the time of the first medical oncology visit. Subjects were eligible if chemotherapy was recommended and prescribed by a participating medical oncologist. Subjects were excluded if cognition was impaired (Mini-Mental State Exam score of <22) or they demonstrated poor proficiency of the English language. Eligibility was determined by clinicians. All study participants provided written informed consent. For the purpose of the aims correlating symptom distress and ability to receive chemotherapy, subjects had to complete at least baseline and 1 follow-up data point.
Study Sites
Subjects were recruited from 6 cancer centers in western Pennsylvania and 1 center in northeast Ohio.
Timing
Symptom incidence and associated distress were assessed by questionnaires including the NCCN Distress Thermometer, McCorkle Symptom Distress Scale (SDS), 30 and Donovan symptom severity symptom reporting questionnaire at 3 time points during chemotherapy. These time points were individualized to prescribed patient chemotherapy at baseline, at the midpoint of chemotherapy (usually anticipated at 6-12 weeks), and at the completion of chemotherapy (usually anticipated at 12-24 weeks). Total scores and individual items were analyzed. Midpoint was calculated as per patient. At the time of the initiation of the current study, the prescribed chemotherapy was analyzed as per patient. The midpoints and endpoints were determined. These were the prescribed time points against which the measurement of the number of doses of prescribed chemotherapy actually received was measured.
Measurements
Sociodemographic factors
Sociodemographic factors as covariates were measured using an investigator-derived sociodemographic questionnaire, a 23-item form that includes sociodemographic variables such as age, marital status, employment status, household composition, religious/spiritual beliefs, health insurance status, and income level. In addition, tumor characteristics, chemotherapy prescription, smoking, weight, height, and menopausal symptoms were abstracted from the medical record.
The McCorkle SDS 30 was developed in 1977 based on interviews with patients regarding their symptom experiences. Scores range from 1 to 5 on a Likert-type scale, with 5 indicating most severe. 30 Total symptom distress can be obtained as the unweighted sum of 13 items.
Total number of symptoms
The total number of symptoms reported (TOTNS) score was tallied from the Donovan symptom severity symptom reporting questionnaire, an investigator-initiated questionnaire assessing 22 symptoms commonly occurring during breast cancer chemotherapy. Each symptom was of equal weight.
Overall cancer-related distress
The NCCN Distress Thermometer is designed to measure an individual's distress during the past week, including the day of administration. The tool is scored from 0 ("no distress") to 10 ("extreme distress") on a Likert scale. 31 
Adherence
Adherence to chemotherapy was collected for each participant from the medical record. Adherence was reported as the percentage of doses of chemotherapy received compared with the total number of doses prescribed at the time of the original prescription. The adherence rate encompassed the prescribed time frame, the time originally projected with the chemotherapy prescription. Participants then were dichotomized (yes/no) with regard to their ability to receive 85% of the prescribed chemotherapy by the prescribed midpoint and prescribed endpoint. Patients receiving chemotherapy were not concurrently receiving radiotherapy or hormonal therapy. Although many of these patients subsequently received endocrine and/or radiotherapy, they did not receive these therapies during chemotherapy and the interval of the current study.
Data Collection and Analysis
Study data were collected at patient clinic visits or occasionally by telephone, all in interview format. Study data were collected using SurveyGold V C 1998-2017 Golden Hills Software electronic data entry and then entered and managed using REDCap electronic data capture tools hosted at the University of Pittsburgh. 32 REDCap (Research Electronic Data Capture) is a secure, Web-based application designed to support data capture. 32 Further data management was conducted using SPSS statistical software (version 22).
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SAS statistical software (version 9.4; SAS Institute Inc, Cary NC) was used for data analysis. Based on the variable's level of measurement and data distribution, descriptive statistics (eg, mean, standard deviation, frequency, and percentage) were used to summarize the data. The linear mixed modeling method was used to deal with randomly missing data in a repeated measures design study; thus, in the current study we used the linear mixed modeling method to examine the changes in the TOTNS score and symptom distress and the individual symptoms as well as the 1-item measure of cancer distress over the 3 time points. Pearson product-moment correlation (r) was calculated to summarize the associations between symptoms, symptom distress, cancer-related distress, and the ability to receive 85% of the prescribed chemotherapy. Covariates considered in the analyses included age, menopausal status, employment status, body mass index, smoking status, number of comorbid diseases listed in the patient history, and type of chemotherapy received.
RESULTS
Subject Characteristics
A total of 151 AA women were consented and randomized for study participation from the 7 study sites. The women were randomized to the ACTS Intervention group (75 women) or care as usual (76 women). The retention rate from enrollment to the end of the study was 81% (Fig. 1) . A total of 133 patients completed at least 2 time points, an eligibility criterion for the analysis of these exploratory aims. After excluding women with metastatic (stage IV) cancer and those with <2 assessments, the sample size for the analysis of these exploratory aims was limited to 121 women.
Based on self-reported sociodemographic surveys, only 24.8% of the women (30 women) had T1 disease. The majority of subjects had estrogen receptor-positive tumors (66 women; 54.5%), which is less than historical controls in white populations of 75%. 32 Slightly more women had human epidermal growth factor receptor 2 (HER2)/neu-positive tumors (37 women; 30.6%) in this AA study population compared with white women (20%-25%). 34 These tumor characteristics indicated worse prognosis than that in white populations. 34 The majority of women were recommended a taxane (119; 98.3%) and alkylating agent (116; 95.9%); approximately one-half received an anthracycline (61; 50.4%) ( Table 1) .
Symptom Distress
The mean scores of the McCorkle SDS deteriorated with increased distress scores over the course of chemotherapy, from 21.5 6 6.2 at baseline to 26.2 6 8.7 at time point 2 (midway through chemotherapy). The scores continued to slightly worsen to 26.8 6 7.9 at the completion of chemotherapy ( Table 2 ). All 11 individual symptoms deteriorated over time except "outlook." The worsening of overall symptom distress was attributed largely to the 4 symptoms of "appearance" (1.3 to 2.5 to 2.6), "bowels" (1.4 to 2.1 to 2.0), "fatigue" (2.1 to 2.7 to 3.0), and "insomnia" (1.9 to 2.6 to 2.4). No covariates were found to be consistently associated with symptom distress.
Total Number of Symptoms
The TOTNS scores followed a similar pattern to the McCorkle SDS trend. The scale range was from 0 to 21. The mean score at baseline was 5.9 6 3.7. The TOTNS score increased to a mean of 9.9 6 4.2 at time point 2 (midway through chemotherapy) and remained high but did not continue to worsen at the end of treatment, with a mean score of 10.0 6 4.1 (Table 2) . No covariates were found to be consistently associated with the total number of symptoms.
Cancer-Related Distress
Cancer-related distress scores demonstrated one interesting pattern. It is interesting to note that scores were highest at baseline at 4.3 6 2.6, falling to 3.7 6 3.0 at the midpoint and remaining stable at 3.7 6 2.8 at the time of chemotherapy completion. No covariates were found to be consistently associated with cancer-related distress. 
Adherence to Chemotherapy
The participant's overall ability to receive the prescribed chemotherapy dose within the prescribed time frame was 86.1% 6 20.6% of the total prescribed dosages at the midpoint during chemotherapy and 85.9% 6 17.3% of the total prescribed dose at the completion of chemotherapy. Among the sociodemographic variables analyzed, positive adherence to chemotherapy was found to be significantly associated (P < .05) with only a fewer number of comorbidities and full employment status. When analyzed according to the ability to receive 85% of the prescribed chemotherapy within a prescribed time period, 66.7% of the participants (80 women) received 85% of the prescribed chemotherapy by the prescribed midpoint.
This dropped to 60.3% of the participants (73 women) by the prescribed endpoint (Table 3) Relationship Between Symptom Incidence, Distress, and Ability to Receive the Full Dose of Chemotherapy by the Midpoint
Pearson correlation revealed significant relationships between the prescribed chemotherapy received and symptom distress scores at baseline (r 5 0.243; P 5 .007), at the midpoint (r 5 0.187; P 5 .042), and at the completion of chemotherapy (r 5 0.180; P 5 .05), thereby indicating that the baseline existence and then further worsening of symptoms as a woman progresses through chemotherapy is negatively related to the ability to receive on-time and full-dose chemotherapy at the midpoint through chemotherapy. The TOTNS score was not found to be correlated with the ability to receive ontime and full-dose chemotherapy by the midpoint. The midpoint cancer-related distress scores (r 5 0.177; P 5 .05) also were found to be correlated with the ability to receive the full dose of chemotherapy by the midpoint (Table 4) .
Relationship Between Symptom Incidence, Distress, and the Ability to Receive the Full Dose of Chemotherapy by the Endpoint
Symptom distress scores at baseline (r 5 0.188; P 5 .040) and at the midpoint (r 5 0.177; P 5 .05) again indicated a relationship with the ability to receive the entire course of chemotherapy on time with at least 85% of the prescribed doses. The total number of symptoms at baseline (r 5 0.189; P 5 .039) was found to have a positive correlation with the ability to receive the full and timely dose of chemotherapy (Table 4) .
DISCUSSION
To the best of our knowledge, the mechanisms by which breast cancer treatment disparity occurs and the clinical significance of the disparity are not yet completely understood or elucidated. Physician prescription of breast cancer treatment and patient factors contributing to the initiation of treatment previously have been explored as possible causes for the racial disparity. However, patient symptoms and treatment-associated distress may cause subsequent cancer-related distress that ultimately affects the amount of prescribed treatment a patient receives. [35] [36] [37] [38] [39] [40] [41] [42] The hypothesis was that there was a correlation between the symptom experience and the ability to receive full-dose and timely chemotherapy. To examine this relationship, all dose reductions, chemotherapy holds, and early termination in each individual patient record had to be extracted and evaluated. To our knowledge, the current study is the first to specifically describe symptom incidence and distress among AA women with breast cancer over 3 time points specifically spanning the duration of chemotherapy. The relationship between symptoms, degree of distress, and chemotherapy adherence rates were reported herein.
The findings of the current study add to the growing literature differentiating treatment intensity between white and AA populations in community practice, outside of clinical trials. Although difficult to distinguish precisely, it appears that 3.5% of white women in community practice receive a dose intensity of <85%, the outcome believed to be associated with poor outcomes, 43 and that AA women are twice as likely to receive a >15% dose reduction during chemotherapy compared with white women. 44 In the current study, 33.3% of the study sample (40 women) did not receive 85% of their chemotherapy by the midpoint, and 39.7% (48 women) of the study sample of AA women received <85% of their projected chemotherapy doses by the projected endpoint. Worse symptom scores were associated with the patient's inability to receive prescribed chemotherapy within the prescribed time frame. Thus it is reasonable to examine the incidence and management of chemotherapy-related symptoms, particularly from baseline through the first one-half of chemotherapy, as contributing to dose reductions and delays among AA women and as important targets for dose disparity mitigation.
The 2 main findings of the current study were that AA women experience a deterioration in overall symptom incidence, particularly over the course of chemotherapy from baseline (before chemotherapy) to the midpoint and that the worsening of overall symptom distress over the course of chemotherapy was associated with an inferior ability to receive prescribed chemotherapy, particularly until the midpoint in chemotherapy.
It is interesting to note the relative stabilization of symptom and cancer-related distress from the midpoint until the end of chemotherapy after an initial deterioration from baseline. There is difficulty in measuring and determining symptoms that are prevalent and troubling over time. These findings have been reported in previous literature, demonstrating a pattern of longitudinal symptom variability among many patients undergoing cancer therapy. 21, 45, 46 It is presumed that an adaptation occurs as women experience chemotherapy and learn self-management and coping skills for troubling symptoms. These self-management and coping skills are key to symptom mitigation. Perhaps this patient education and counseling needs to be offered in a culturally sensitive manner. This could be an important interventional target.
Although this was a prospective study, it had limitations. A comparable group of white women with breast cancer was not included. Last, although chemotherapy adherence was relatively poor, the ACTS intervention (which approximately one-half of the patients in the current study received) was designed to encourage adherence to prescribed therapy and therefore may have artificially inflated the actual adherence rates among those women who received the intervention.
Conclusions
To the best of our knowledge, the current study is the first to report that an increased level of symptom incidence and distress correlates with a worse ability to receive prescribed breast cancer chemotherapy among AA women. The symptom incidence and distress appears to deteriorate from baseline to the midpoint and then stabilizes from the midpoint of chemotherapy to the end of treatment. This relationship may contribute to the breast cancer survival disparity that exists between AA women and non-Hispanic white women. Further studies are needed to confirm these findings. Improvements in symptom management may be a potential target for an intervention to mitigate this potential racial disparity in women with breast cancer.
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